Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study

BACKGROUND AND AIMS: Innovative treatment modalities have not yet shown a clinical benefit in patients with septic shock. To reduce severe cytokinaemia, CytoSorb as an add-on to continuous renal replacement therapy (CRRT) showed promising results in case reports. However, there are no clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Brouwer, Willem Pieter, Duran, Servet, Kuijper, Martijn, Ince, Can
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749645/
https://www.ncbi.nlm.nih.gov/pubmed/31533846
http://dx.doi.org/10.1186/s13054-019-2588-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749645/
https://www.ncbi.nlm.nih.gov/pubmed/31533846
http://dx.doi.org/10.1186/s13054-019-2588-1

Ejemplares similares